{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T14:15:17Z","timestamp":1781360117784,"version":"3.54.1"},"reference-count":64,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["D43TW000233"],"award-info":[{"award-number":["D43TW000233"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R25 TW009338"],"award-info":[{"award-number":["R25 TW009338"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R01 DA029910"],"award-info":[{"award-number":["R01 DA029910"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R01 DA033679"],"award-info":[{"award-number":["R01 DA033679"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["K24 DA017072"],"award-info":[{"award-number":["K24 DA017072"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000061","name":"Fogarty International Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000061","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journalofsubstanceabusetreatment.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Substance Abuse Treatment"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1016\/j.jsat.2019.05.008","type":"journal-article","created":{"date-parts":[[2019,5,9]],"date-time":"2019-05-09T22:38:43Z","timestamp":1557441523000},"page":"34-41","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Treating opioid dependence with extended-release naltrexone (XR-NTX) in Ukraine: Feasibility and three-month outcomes"],"prefix":"10.1016","volume":"104","author":[{"given":"Iuliia","family":"Makarenko","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9290-8902","authenticated-orcid":false,"given":"Iryna","family":"Pykalo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra A.","family":"Springer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8900-5515","authenticated-orcid":false,"given":"Alyona","family":"Mazhnaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruthanne","family":"Marcus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergii","family":"Filippovich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergii","family":"Dvoriak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick L.","family":"Altice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl. 1","key":"10.1016\/j.jsat.2019.05.008_bb0005","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1097\/QAI.0b013e318209751e","article-title":"HIV treatment outcomes among HIV-infected, opioid-dependent patients receiving buprenorphine\/naloxone treatment within HIV clinical care settings: Results from a multisite study","volume":"56","author":"Altice","year":"2011","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"2","key":"10.1016\/j.jsat.2019.05.008_bb0010","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0749-3797(18)30622-6","article-title":"Screening for depression in well older adults: Evaluation of a short form of the CES-D (Center for Epidemiologic Studies Depression Scale)","volume":"10","author":"Andresen","year":"1994","journal-title":"Am J Prev Med"},{"key":"10.1016\/j.jsat.2019.05.008_bb0015","doi-asserted-by":"crossref","unstructured":"Anton, R. F., O'Malley, S. S., Ciraulo, D. A., Cisler, R. A., Couper, D., Donovan, D. M., \u2026 Zweben, A. (2006). Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA, 295(17), 2003-2017. doi:295\/17\/2003 [pii] 10.1001\/jama.295.17.2003 [doi]","DOI":"10.1001\/jama.295.17.2003"},{"key":"10.1016\/j.jsat.2019.05.008_bb0020","series-title":"The alcohol use disorders identification test (AUDIT)","author":"Babor","year":"2001"},{"issue":"10","key":"10.1016\/j.jsat.2019.05.008_bb0025","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1111\/add.12243","article-title":"At the crossroads: HIV prevention and treatment for people who inject drugs in Ukraine","volume":"108","author":"Bojko","year":"2013","journal-title":"Addiction"},{"issue":"3","key":"10.1016\/j.jsat.2019.05.008_bb0030","first-page":"255","article-title":"\u201cBureaucracy & beliefs\u201d: Assessing the barriers to accessing opioid substitution therapy by people who inject drugs in Ukraine","volume":"22","author":"Bojko","year":"2015","journal-title":"Drugs: Education, Prevention and Policy"},{"key":"10.1016\/j.jsat.2019.05.008_bb0035","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jsat.2016.03.003","article-title":"The future of opioid agonist therapies in Ukraine: A qualitative assessment of multilevel barriers and ways forward to promote retention in treatment","volume":"66","author":"Bojko","year":"2016","journal-title":"J Subst Abuse Treat"},{"issue":"4","key":"10.1016\/j.jsat.2019.05.008_bb0040","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.drugpo.2006.12.011","article-title":"HIV treatment access and scale-up for delivery of opiate substitution therapy with buprenorphine for IDUs in Ukraine\u2013Programme description and policy implications","volume":"18","author":"Bruce","year":"2007","journal-title":"Int J Drug Policy"},{"issue":"1","key":"10.1016\/j.jsat.2019.05.008_bb0045","doi-asserted-by":"crossref","first-page":"50","DOI":"10.15288\/jsad.2009.70.50","article-title":"Three brief alcohol screens for detecting hazardous drinking in incarcerated women","volume":"70","author":"Caviness","year":"2009","journal-title":"Journal of Studies on Alcohol and Drugs"},{"issue":"8","key":"10.1016\/j.jsat.2019.05.008_bb0050","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1517\/13543784.16.8.1285","article-title":"Sustained-release naltrexone: Novel treatment for opioid dependence","volume":"16","author":"Comer","year":"2007","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.jsat.2019.05.008_bb0055","doi-asserted-by":"crossref","unstructured":"Connock, M., Juarez-Garcia, A., Jowett, S., Frew, E., Liu, Z., Taylor, R. J., \u2026 Taylor, R. S. (2007). Methadone and buprenorphine for the management of opioid dependence: A systematic review and economic evaluation. Health Technology Assessment, 11(9), 1\u2013171, (iii-iv).","DOI":"10.3310\/hta11090"},{"key":"10.1016\/j.jsat.2019.05.008_bb0060","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.jsat.2015.12.004","article-title":"Predictors of continued use of extended-released naltrexone (XR-NTX) for opioid-dependence: An analysis of heroin and non-heroin opioid users in Los Angeles County","volume":"63","author":"Cousins","year":"2016","journal-title":"J Subst Abuse Treat"},{"issue":"12","key":"10.1016\/j.jsat.2019.05.008_bb0065","doi-asserted-by":"crossref","first-page":"e1192","DOI":"10.1016\/S2214-109X(17)30375-3","article-title":"Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: A multistage systematic review","volume":"5","author":"Degenhardt","year":"2017","journal-title":"Lancet Glob Health"},{"issue":"2","key":"10.1016\/j.jsat.2019.05.008_bb0070","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.cct.2014.09.002","article-title":"Design and methods of a double blind randomized placebo-controlled trial of extended-release naltrexone for HIV-infected, opioid dependent prisoners and jail detainees who are transitioning to the community","volume":"39","author":"Di Paola","year":"2014","journal-title":"Contemp Clin Trials"},{"issue":"3","key":"10.1016\/j.jsat.2019.05.008_bb0075","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0004705","article-title":"Assessing the quality of decision support technologies using the International Patient Decision Aid Standards instrument (IPDASi)","volume":"4","author":"Elwyn","year":"2009","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/j.jsat.2019.05.008_bb0080","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1111\/j.1360-0443.2010.03015.x","article-title":"Treatment of opioid dependence in adolescents and young adults with extended release naltrexone: Preliminary case-series and feasibility","volume":"105","author":"Fishman","year":"2010","journal-title":"Addiction"},{"key":"10.1016\/j.jsat.2019.05.008_bb0085","article-title":"Do patient characteristics moderate the effect of extended-release naltrexone (XR-NTX) for opioid use disorder?","author":"Friedmann","year":"2017","journal-title":"J Subst Abuse Treat."},{"issue":"13","key":"10.1016\/j.jsat.2019.05.008_bb0090","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1001\/jama.293.13.1617","article-title":"Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: A randomized controlled trial","volume":"293","author":"Garbutt","year":"2005","journal-title":"Jama"},{"issue":"2","key":"10.1016\/j.jsat.2019.05.008_bb0095","doi-asserted-by":"crossref","first-page":"148","DOI":"10.2471\/BLT.12.109553","article-title":"Mitigating the risk of HIV infection with opioid substitution treatment","volume":"91","author":"Gowing","year":"2013","journal-title":"Bull World Health Organ"},{"issue":"3","key":"10.1016\/j.jsat.2019.05.008_bb0100","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1080\/13556210310001602257","article-title":"A pilot study to assess the impact of naltrexone implant on accidental opiate overdose in \u2018high-risk\u2019 adolescent heroin users","volume":"8","author":"Hulse","year":"2003","journal-title":"Addict Biol"},{"issue":"3","key":"10.1016\/j.jsat.2019.05.008_bb0105","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.drugalcdep.2005.02.009","article-title":"Reducing hospital presentations for opioid overdose in patients treated with sustained release naltrexone implants","volume":"79","author":"Hulse","year":"2005","journal-title":"Drug Alcohol Depend"},{"issue":"2","key":"10.1016\/j.jsat.2019.05.008_bb0110","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1080\/08897077.2015.1010031","article-title":"Cost-effectiveness of injectable extended-release naltrexone compared with methadone maintenance and buprenorphine maintenance treatment for opioid dependence","volume":"36","author":"Jackson","year":"2015","journal-title":"Subst Abus"},{"key":"10.1016\/j.jsat.2019.05.008_bb0115","doi-asserted-by":"crossref","first-page":"157","DOI":"10.15288\/jsas.2005.s15.157","article-title":"The COMBINE SAFTEE: A structured instrument for collecting adverse events adapted for clinical studies in the alcoholism field","volume":"15","author":"Johnson","year":"2005","journal-title":"Journal of Studies on Alcohol. Supplement"},{"issue":"5","key":"10.1016\/j.jsat.2019.05.008_bb0120","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.annepidem.2004.09.004","article-title":"Modeling sources of self-report bias in a survey of drug use epidemiology","volume":"15","author":"Johnson","year":"2005","journal-title":"Ann Epidemiol"},{"key":"10.1016\/j.jsat.2019.05.008_bb0125","series-title":"Global AIDS Update 2016","author":"Joint United Nations Programme on HIV\/AIDS (UNAIDS)","year":"2016"},{"key":"10.1016\/j.jsat.2019.05.008_bb0130","article-title":"Primary care-based models for the treatment of opioid use disorder: A scoping review","author":"Korthuis","year":"2016","journal-title":"Ann Intern Med."},{"issue":"9","key":"10.1016\/j.jsat.2019.05.008_bb0135","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1111\/add.12208","article-title":"Injectable extended-release naltrexone (XR-NTX) for opioid dependence: long-term safety and effectiveness","volume":"108","author":"Krupitsky","year":"2013","journal-title":"Addiction"},{"issue":"9776","key":"10.1016\/j.jsat.2019.05.008_bb0140","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1016\/S0140-6736(11)60358-9","article-title":"Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial","volume":"377","author":"Krupitsky","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.jsat.2019.05.008_bb0145","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/1477-7517-8-32","article-title":"The Soviet doctor and the treatment of drug addiction: \u201cA difficult and most ungracious task\u201d","volume":"8","author":"Latypov","year":"2011","journal-title":"Harm Reduct J"},{"key":"10.1016\/j.jsat.2019.05.008_bb0150","doi-asserted-by":"crossref","unstructured":"Lawrinson, P., Ali, R., Buavirat, A., Altice, F. L., Chiamwongpaet, S., Dvoryak, S., \u2026 Zhao, C. (2008). Key findings from the WHO collaborative study on substitution therapy for opioid dependence and HIV\/AIDS. Addiction, 103(9), 1484\u20131492. doi:ADD2249 [pii] https:\/\/doi.org\/10.1111\/j.1360-0443.2008.02249.x [doi].","DOI":"10.1111\/j.1360-0443.2008.02249.x"},{"issue":"13","key":"10.1016\/j.jsat.2019.05.008_bb0155","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1056\/NEJMoa1505409","article-title":"Extended-release naltrexone to prevent opioid relapse in criminal justice offenders","volume":"374","author":"Lee","year":"2016","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.jsat.2019.05.008_bb0160","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1111\/add.12894","article-title":"Opioid treatment at release from jail using extended-release naltrexone: A pilot proof-of-concept randomized effectiveness trial","volume":"110","author":"Lee","year":"2015","journal-title":"Addiction"},{"issue":"10118","key":"10.1016\/j.jsat.2019.05.008_bb0165","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0140-6736(17)32812-X","article-title":"Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): A multicentre, open-label, randomised controlled trial","volume":"391","author":"Lee","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.jsat.2019.05.008_bb0170","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciw416","article-title":"Impact of opioid substitution therapy on antiretroviral therapy outcomes: A systematic review and meta-analysis","author":"Low","year":"2016","journal-title":"Clin Infect Dis, In press."},{"key":"10.1016\/j.jsat.2019.05.008_bb0175","doi-asserted-by":"crossref","unstructured":"Makarenko, I., Mazhnaya, A., Marcus, R., Bojko, M. J., Madden, L., Filippovych, S., \u2026 Altice, F. L. (2017). Willingness to pay for opioid agonist treatment among opioid dependent people who inject drugs in Ukraine. International J Drug Policy(In press.).","DOI":"10.1016\/j.drugpo.2017.05.037"},{"key":"10.1016\/j.jsat.2019.05.008_bb0180","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.drugalcdep.2016.06.011","article-title":"Determinants of willingness to enroll in opioid agonist treatment among opioid dependent people who inject drugs in Ukraine","volume":"165","author":"Makarenko","year":"2016","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.jsat.2019.05.008_bb0185","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.jsat.2018.01.003","article-title":"A qualitative assessment of attitudes about and preferences for extended-release naltrexone, a new pharmacotherapy to treat opioid use disorders in Ukraine","volume":"86","author":"Marcus","year":"2018","journal-title":"J Subst Abuse Treat"},{"issue":"4","key":"10.1016\/j.jsat.2019.05.008_bb0190","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1046\/j.1360-0443.1998.9345157.x","article-title":"The efficacy of methadone maintenance interventions in reducing illicit opiate use, HIV risk behavior and criminality: A meta-analysis","volume":"93","author":"Marsch","year":"1998","journal-title":"Addiction"},{"key":"10.1016\/j.jsat.2019.05.008_bb0195","doi-asserted-by":"crossref","unstructured":"Mattick, R. P., Breen, C., Kimber, J., & Davoli, M. (2014). Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev(2), Cd002207. doi:https:\/\/doi.org\/10.1002\/14651858.CD002207.pub4","DOI":"10.1002\/14651858.CD002207.pub4"},{"issue":"1","key":"10.1016\/j.jsat.2019.05.008_bb0200","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1097\/00005053-198001000-00006","article-title":"An improved diagnostic evaluation instrument for substance abuse patients. The addiction severity index","volume":"168","author":"McLellan","year":"1980","journal-title":"The Journal of Nervous and Mental Disease"},{"key":"10.1016\/j.jsat.2019.05.008_bb0205","author":"Ministry of Finance of Ukraine"},{"issue":"6","key":"10.1016\/j.jsat.2019.05.008_bb0210","doi-asserted-by":"crossref","first-page":"991","DOI":"10.15288\/jsad.2012.73.991","article-title":"Hepatic safety of injectable extended-release naltrexone in patients with chronic hepatitis C and HIV infection","volume":"73","author":"Mitchell","year":"2012","journal-title":"Journal of Studies on Alcohol and Drugs"},{"issue":"5","key":"10.1016\/j.jsat.2019.05.008_bb0215","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1097\/jcp.0b013e31814ce50d","article-title":"Efficacy of extended-release naltrexone in alcohol-dependent patients who are abstinent before treatment","volume":"27","author":"O'Malley","year":"2007","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.jsat.2019.05.008_bb0220","doi-asserted-by":"crossref","DOI":"10.1007\/s10461-016-1375-0","article-title":"Attitudes toward addiction, methadone treatment, and recovery among HIV-infected Ukrainian prisoners who inject drugs: Incarceration effects and exploration of mediators","author":"Polonsky","year":"2016","journal-title":"AIDS Behav, In Press."},{"issue":"3","key":"10.1016\/j.jsat.2019.05.008_bb0225","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/0306-4603(94)00072-7","article-title":"Initial motivations for alcohol treatment: Relations with patient characteristics, treatment involvement, and dropout","volume":"20","author":"Ryan","year":"1995","journal-title":"Addictive Behaviors"},{"issue":"4","key":"10.1016\/j.jsat.2019.05.008_bb0230","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/0306-4603(82)90005-3","article-title":"The drug abuse screening test","volume":"7","author":"Skinner","year":"1982","journal-title":"Addictive Behaviors"},{"key":"10.1016\/j.jsat.2019.05.008_bb0235","series-title":"Monitoring of liver function tests in patients receiving naltrexone or extended-release naltrexone","author":"Springer","year":"2014"},{"issue":"1","key":"10.1016\/j.jsat.2019.05.008_bb0240","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1097\/QAI.0000000000001634","article-title":"Extended-release naltrexone improves viral suppression among incarcerated persons living with HIV with opioid use disorders transitioning to the community: Results of a double-blind, placebo-controlled randomized trial","volume":"78","author":"Springer","year":"2018","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"5","key":"10.1016\/j.jsat.2019.05.008_bb0245","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0038335","article-title":"Retention on buprenorphine is associated with high levels of maximal viral suppression among HIV-infected opioid dependent released prisoners","volume":"7","author":"Springer","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jsat.2019.05.008_bb0250","doi-asserted-by":"crossref","unstructured":"Stacey, D., Bennett, C. L., Barry, M. J., Col, N. F., Eden, K. B., Holmes-Rovner, M., \u2026 Thomson, R. (2011). Decision aids for people facing health treatment or screening decisions. Cochrane Database Syst Rev(10), CD001431. doi:https:\/\/doi.org\/10.1002\/14651858.CD001431.pub3","DOI":"10.1002\/14651858.CD001431.pub3"},{"key":"10.1016\/j.jsat.2019.05.008_bb0255","doi-asserted-by":"crossref","unstructured":"Sullivan, M., Bisaga, A., Pavlicova, M., Choi, C. J., Mishlen, K., Carpenter, K. M., \u2026 Nunes, E. V. (2017). Long-acting injectable naltrexone induction: A randomized trial of outpatient opioid detoxification with naltrexone versus buprenorphine. Am J Psychiatry, appiajp201616050548. doi:https:\/\/doi.org\/10.1176\/appi.ajp.2016.16050548","DOI":"10.1176\/appi.ajp.2016.16050548"},{"issue":"10","key":"10.1016\/j.jsat.2019.05.008_bb0260","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1007\/s40263-013-0110-x","article-title":"Extended-release intramuscular naltrexone (VIVITROL(R)): A review of its use in the prevention of relapse to opioid dependence in detoxified patients","volume":"27","author":"Syed","year":"2013","journal-title":"CNS Drugs"},{"issue":"12","key":"10.1016\/j.jsat.2019.05.008_bb0265","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1001\/jamapsychiatry.2017.3206","article-title":"Effectiveness of injectable extended-release naltrexone vs daily buprenorphine-naloxone for opioid dependence: A randomized clinical noninferiority trial","volume":"74","author":"Tanum","year":"2017","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.jsat.2019.05.008_bb0270","first-page":"219","article-title":"Naltrexone extended-release injection: An option for the management of opioid abuse","volume":"2","author":"Taylor","year":"2011","journal-title":"Subst Abuse Rehabil"},{"key":"10.1016\/j.jsat.2019.05.008_bb0275","series-title":"From Ukrainian Center for Disease Control","article-title":"Opioid substitution therapy statistics","author":"Ukrainian Centers for Disease Control (UCDC)","year":"2015"},{"key":"10.1016\/j.jsat.2019.05.008_bb0280","series-title":"Word drug report 2016","author":"United Nations Office on Drugs and Crime (UNODC)","year":"2016"},{"issue":"1","key":"10.1016\/j.jsat.2019.05.008_bb0285","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.jsat.2014.02.008","article-title":"An evaluation of hepatic enzyme elevations among HIV-infected released prisoners enrolled in two randomized placebo-controlled trials of extended release naltrexone","volume":"47","author":"Vagenas","year":"2014","journal-title":"J Subst Abuse Treat"},{"key":"10.1016\/j.jsat.2019.05.008_bb0290","author":"Verkhovna Rada of Ukraine"},{"key":"10.1016\/j.jsat.2019.05.008_bb0295","doi-asserted-by":"crossref","unstructured":"Vo, H. T., Robbins, E., Westwood, M., Lezama, D., & Fishman, M. (2016). Relapse prevention medications in community treatment for young adults with opioid addiction. Subst Abus, 0. doi:https:\/\/doi.org\/10.1080\/08897077.2016.1143435","DOI":"10.1080\/08897077.2016.1143435"},{"key":"10.1016\/j.jsat.2019.05.008_bb0300","series-title":"SF-12: How to score the SF-12 physical and mental health summary scales","author":"Ware","year":"1998"},{"issue":"2","key":"10.1016\/j.jsat.2019.05.008_bb0305","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1080\/02791072.2003.10400007","article-title":"The Clinical Opiate Withdrawal Scale (COWS)","volume":"35","author":"Wesson","year":"2003","journal-title":"J Psychoactive Drugs"},{"key":"10.1016\/j.jsat.2019.05.008_bb0310","series-title":"WMA declaration of Helsinki - Ethical principles for medical research involving human subjects Helsinki","author":"World Medical Association","year":"1964"},{"issue":"2","key":"10.1016\/j.jsat.2019.05.008_bb0315","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.jsat.2006.08.002","article-title":"A comprehensive review of the psychometric properties of the drug abuse screening test","volume":"32","author":"Yudko","year":"2007","journal-title":"J Subst Abuse Treat"},{"issue":"7","key":"10.1016\/j.jsat.2019.05.008_bb0320","article-title":"Validating a shortened depression scale (10 item CES-D) among HIV-positive people in British Columbia, Canada","volume":"7","author":"Zhang","year":"2012","journal-title":"PLoS One"}],"container-title":["Journal of Substance Abuse Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0740547218305944?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0740547218305944?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T19:49:48Z","timestamp":1760039388000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0740547218305944"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":64,"alternative-id":["S0740547218305944"],"URL":"https:\/\/doi.org\/10.1016\/j.jsat.2019.05.008","relation":{},"ISSN":["0740-5472"],"issn-type":[{"value":"0740-5472","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treating opioid dependence with extended-release naltrexone (XR-NTX) in Ukraine: Feasibility and three-month outcomes","name":"articletitle","label":"Article Title"},{"value":"Journal of Substance Abuse Treatment","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jsat.2019.05.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}